Author:
Singh Aman P.,Maass Katie F.,Betts Alison M.,Wittrup K. Dane,Kulkarni Chethana,King Lindsay E.,Khot Antari,Shah Dhaval K.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Sohayla Rostami IQ, Robert Sikorski. The clinical landscape of antibody-drug conjugates 2014. Available from: http://adcreview.com/articles/doi-10-14229jadc-2014-8-1-001/.
2. Singh AP, Shin YG, Shah DK. Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm Res. 2015.
3. Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;29(9):2354–66.
4. Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacodyn. 2012;39(6):643–59.
5. Shah DK, King LE, Han X, Wentland JA, Zhang Y, Lucas J, et al. A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate. AAPS J. 2014;16(3):453–63.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献